Ionis Pharmaceuticals, Inc.
Modulation of alpha synuclein expression
Last updated:
Abstract:
Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
Status:
Grant
Type:
Utility
Filling date:
18 Apr 2017
Issue date:
27 Oct 2020